

# Phase I Trial: Quotient Code QSC303217

<b>Submission date</b> 24/06/2025	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 01/07/2025	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 01/07/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## Contact information

### Type(s)

Public, Scientific

### Contact name

Dr Terrie Kellmeyer

### Contact details

Aardvark Therapeutics, Inc., 4370 La Jolla Village Drive, Suite 1050  
San Diego  
United States of America  
92122  
+1 (858) 225-7696  
Info@AardvarkTherapeutics.com

### Type(s)

Principal investigator

### Contact name

Dr David Everton

### Contact details

Quotient Sciences Limited, Mere Way, Ruddington Fields, Ruddington  
Nottingham  
United Kingdom  
NG11 6JS  
+44 (0)330 303 1000  
recruitment@weneedyou.co.uk

# Additional identifiers

## Integrated Research Application System (IRAS)

1011885

## Protocol serial number

Sponsor Code: AVK-101-102, Quotient Code: QSC303217

# Study information

## Scientific Title

Phase I Trial: Quotient Code QSC303217

## Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## Ethics approval required

Ethics approval required

## Ethics approval(s)

approved 19/06/2025, London – Hampstead Regulatory Ethics Committee (REC) (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)20 7104 8171; hampstead.rec@hra.nhs.uk), ref: 25/LO/0198

## Study design

Two-part single-centre mass balance recovery and food effect study in healthy volunteers

## Primary study design

Interventional

## Study type(s)

Other

## Health condition(s) or problem(s) studied

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

## Intervention Type

Drug

## Phase

Phase I

**Drug/device/biological/vaccine name(s)**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

**Primary outcome(s)**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

**Key secondary outcome(s)**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

**Completion date**

22/08/2025

**Eligibility**

**Key inclusion criteria**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

**Participant type(s)**

Healthy volunteer

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

65 years

**Sex**

All

**Key exclusion criteria**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

**Date of first enrolment**

01/07/2025

**Date of final enrolment**

22/08/2025

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre****Quotient Sciences Limited**

Mere Way, Ruddington Fields, Ruddington

Nottingham

United Kingdom

NG11 6JS

## Sponsor information

**Organisation**

Aardvark Therapeutics, Inc.

## Funder(s)

**Funder type**

Industry

**Funder Name**

Aardvark Therapeutics, Inc.

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

**IPD sharing plan summary**

Not expected to be made available